Lovastatin, simvastatin and simvastatin-6-oxide nitro-oxo-derivative and preparation method thereof

A technology of simvastatin and lovastatin, applied in the field of statin hypolipidemic drugs, can solve the problems of difficult separation and increased creatine kinase.

Active Publication Date: 2009-12-30
四川抗菌素工业研究所有限公司
View PDF2 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, because lipid-lowering therapy itself can affect many aspects of the AS process, it is difficult to separate these effects from its lipid-lowering effect.
[0005] However, statins also have adverse reactions, such as: hepatotoxicity, nephrotoxicity, potential carcinogenicity, and myotoxicity, etc., the most important one is myotoxicity, and the clinical manifestations are myalgia, muscle tenderness, muscle weakness, and often accompanied by There is an increase in creatine kinase (CK), and the most serious is rhabdomyolysis. Cerivastatin was withdrawn from the market in 2001 because of the severe rhabdomyolysis it caused

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Lovastatin, simvastatin and simvastatin-6-oxide nitro-oxo-derivative and preparation method thereof
  • Lovastatin, simvastatin and simvastatin-6-oxide nitro-oxo-derivative and preparation method thereof
  • Lovastatin, simvastatin and simvastatin-6-oxide nitro-oxo-derivative and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0121](3R,5R)-3,5-dihydroxy-7-[(1S,2S,6R,8S,8αR)-2,6-dimethyl-8-(2,2-dimethylbutyryloxy )-1,2,6,7,8,8α-hexahydro-1-naphthyl]heptanoic acid-4-(nitrooxy)butyl ester (simvastatin-4-(nitrooxy)butyl ester )Synthesis

[0122]

[0123] 1a) (3R,5R)-3,5-dihydroxy-7-[(1S,2S,6R,8S,8αR)-2,6-dimethyl-8-(2,2-dimethylbutyryl Oxy)-1,2,6,7,8,8α-hexahydro-1-naphthyl]heptanoic acid-4-bromobutyl ester

[0124] A solution of 1,4-dibromobutane (0.75ml, 6.3mmol) in N,N'-dimethylformamide (6ml) was added dropwise to a solution of simvastatin sodium (1.60g, 3.5mmol) in N,N' -Dimethylformamide (9ml) solution, the reaction mixture was stirred at room temperature for 24 hours. Water (15ml) was added to the reaction solution, followed by extraction with ether (15ml×3), the organic phase was dried over anhydrous sodium sulfate, filtered and the filtrate was concentrated under reduced pressure. The residue was separated and purified by silica gel column, and eluted with n-hexane / ethyl acetate 1 / 1. 0...

Embodiment 2

[0129] (3R,5R)-3,5-dihydroxy-7-[(1S,2S,6R,8S,8αR)-2,6-dimethyl-8-(2,2-dimethylbutyryloxy )-1,2,6,7,8,8α-hexahydro-1-naphthyl]heptanoic acid-2-[2-(nitrooxy)ethoxy]ethyl ester (simvastatin-2-[ Synthesis of 2-(nitrooxy)ethoxy]ethyl ester)

[0130]

[0131] 2a) (3R,5R)-3,5-dihydroxy-7-[(1S,2S,6R,8S,8αR)-2,6-dimethyl-8-(2,2-dimethylbutyryl Oxy)-1,2,6,7,8,8α-hexahydro-1-naphthyl]heptanoic acid-2-(2-bromoethoxy)ethyl ester to simvastatin sodium salt (0.55g, 1.2 mmol) in N,N'-dimethylformamide (10ml) was added dropwise to 2,2'-dibromodiethyl ether (0.3ml, 2.4mmol) in N,N'-dimethylformamide (10ml ) solution, and the reaction mixture was stirred at room temperature for 48 hours. The reaction solution was concentrated under reduced pressure and then treated with water and ethyl acetate. The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain 1.3 g of oil, which was directly used for the next reaction without separation. ...

Embodiment 3

[0136] (3R,5R)-3,5-dihydroxy-7-[(1S,2S,6R,8S,8αR)-2,6-dimethyl-8-(2,2-dimethylbutyryloxy )-1,2,6,7,8,8α-hexahydro-1-naphthyl]heptanoic acid-4-(nitrooxymethyl)benzyl ester (simvastatin-4-(nitrooxymethyl) base) benzyl ester) synthesis

[0137]

[0138] 3a) (3R,5R)-3,5-dihydroxy-7-[(1S,2S,6R,8S,8αR)-2,6-dimethyl-8-(2,2-dimethylbutyryl Oxy)-1,2,6,7,8,8α-hexahydro-1-naphthyl]heptanoic acid-4-(bromomethyl)benzyl ester

[0139] To a solution of simvastatin sodium salt (0.55g, 1.2mmol) in N,N'-dimethylformamide (10ml) was added dropwise a solution of p-dichlorobenzyl (0.42g, 2.4mmol) in N,N'-di Methylformamide (10ml) solution was added and the reaction mixture was stirred at room temperature for 24 hours. The reaction solution was treated with water and ethyl acetate, and the organic phase was dried over anhydrous sodium sulfate and then concentrated under reduced pressure to obtain 2.0 g of oil, which was directly used for the next reaction without separation.

[0140] 3b) (3R...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention describes lovastatin, simvastatin and simvastatin-6-oxide (L-669262) nitro-oxo-derivative of which the general formula is shown in formula (I) and the drugs can increase the non-lipid activity of statins such as anti-inflammatory and the like. The invention also relates to a preparation method of the drugs.

Description

Technical field: [0001] The invention relates to a novel nitrooxy derivative of a statin blood lipid-lowering drug and a preparation method thereof. The derivative can be used for lowering blood fat and can improve non-lipid-regulating activities of statin drugs such as anti-inflammatory. Background technique: [0002] Statins refer to a group of compounds, the main compounds include Mevastatin, Lovastatin, Simvastatin, Pravastatin, Fluvastatin, Atorvastatin Atorvastatin, Cerivastatin, Rosuvastatin, and Pitavastatin. Among them, mevastatin, lovastatin and pravastatin are compounds derived from microorganisms, simvastatin is a semi-synthetic compound, and the other compounds are fully synthetic compounds. L-669262 is a derivative of simvastatin-6-oxo (iso-simvastatin-6-one), isolated from the sodium salt of simvastatin through microbial transformation, L-669262 inhibits the in vitro activity of HMG-CoA reductase 6-7 times that of simvastatin (IC 50 0.66 ng / ml and 0.10 ng / m...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07C203/04C07C201/02C07D213/30A61K31/22A61K31/44A61P3/06A61P29/00
Inventor 陈宇瑛任文杰李坤
Owner 四川抗菌素工业研究所有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap